Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Hidetaka Kawabata
Toranomon Hospital - Department of Breast and Endocrine Surgery
Tokyo, 105-8470
Japan
Learn more about SSRN Profiles
SCHOLARLY PAPERS
2
DOWNLOADS
152
TOTAL CITATIONS
0
Feedback
Scholarly Papers (2)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Phase 2 Study of Nivolumab Plus Bevacizumab Plus Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer
Number of pages: 34
Posted: 04 May 2021
Yukinori Ozaki
,
Junji Tsurutani
,
Toru Mukohara
,
Tsutomu Iwasa
,
Masato Takahashi
,
Yuko Tanabe
, Hidetaka Kawabata,
Norikazu Masuda
,
Manabu Futamura
,
Hironobu Minami
,
Koji Matsumoto
,
Kenichi Yoshimura
,
Shigehisa Kitano
and
Toshimi Takano
Toranomon Hospital - Department of Medical Oncology, Showa University - Advanced Cancer Translational Research Institute, National Cancer Center Hospital East - Department of Breast and Medical Oncology, Kindai University - Department of Medical Oncology, National Hospital Organization Hokkaido Cancer Center - Department of Breast Surgery, Toranomon Hospital - Department of Medical Oncology, Toranomon Hospital - Department of Breast and Endocrine Surgery, Nagoya University - Graduate School of Medicine, Gifu University - Department of Surgical Oncology, Kobe University - Medical Oncology/Hematology, Hyogo Cancer Center - Department of Medical Oncology, Hiroshima University Hospital - Center for Integrated Medical Research, National Cancer Center Hospital - Department of Experimental Therapeutics and Toranomon Hospital - Department of Medical Oncology
Downloads
106
(659,487)
View PDF
Download
Abstract:
2.
Safety and Efficacy of Nivolumab Plus Bevacizumab, Paclitaxel for HER2-Negative Metastatic Breast Cancer: Primary Result and Biomarker Data of a Phase 2 Trial
Number of pages: 51
Posted: 03 Mar 2022
Yukinori Ozaki
,
Junji Tsurutani
,
Toru Mukohara
,
Tsutomu Iwasa
,
Masato Takahashi
,
Yuko Tanabe
, Hidetaka Kawabata,
Norikazu Masuda
,
Manabu Futamura
,
Hironobu Minami
,
Koji Matsumoto
,
Kenichi Yoshimura
,
Shigehisa Kitano
and
Toshimi Takano
Toranomon Hospital - Department of Medical Oncology,
affiliation not provided to SSRN
, National Cancer Center Hospital East - Department of Breast and Medical Oncology, Kindai University - Department of Medical Oncology, Hokkaido University - Hokkaido University Hospital, Toranomon Hospital - Department of Medical Oncology, Toranomon Hospital - Department of Breast and Endocrine Surgery, Nagoya University - Graduate School of Medicine, Gifu University - Department of Surgical Oncology, Kobe University - Medical Oncology/Hematology,
affiliation not provided to SSRN
, Hiroshima University Hospital - Center for Integrated Medical Research, National Cancer Center Hospital - Department of Experimental Therapeutics and Toranomon Hospital - Department of Medical Oncology
Downloads
46
(1,108,890)
View PDF
Download
Abstract:
Nivolumab, Bevacizumab, immunotherapy, VEGF, Metastatic breast cancer
Feedback